- 1 Title: Estimating post-treatment recurrence after multidrug-resistant tuberculosis
- treatment among patients with and without HIV: the impact of assumptions about death and 2 3 missing follow-up
- 4
- 5
- Authors: Sara M. Sauer¹, Carole D. Mitnick¹, Uzma Khan², Catherine Hewison³, Mathieu Bastard⁴, David Holtzman⁵, Stephanie Law¹, Munira Khan⁶, Shrivani Padayachee⁶, Saman 6
- 7
- 8
- Ahmed⁷, Afshan K. Isani⁸, Aga Krisnanda⁹, Stalz Charles Vilbrun¹⁰, Sagit Bektasov¹¹, Andargachew Kumsa¹², Wisney Docteur¹³, Karen Tintaya¹⁴, Mark McNicol¹⁵, Hakob Atshemyan¹⁶, Tatiana Voynilo¹⁷, Thin Thin Thwe¹⁸, Kwonjune Seung^{19,20}, Michael Rich^{19,20}, Helena Huerga^{4*}, Palwasha Khan^{2,21*}, Molly Franke^{1*} 9
- 10
- 11
- ¹Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA 12
- 13 ²Interactive Research and Development (IRD) Global, Singapore, Singapore
- 14 ³Médecins Sans Frontières, Paris, France
- 15 ⁴Epicentre, Paris, France
- ⁵Partners in Health, Maseru, Lesotho 16
- 17 ⁶IRD Global, Durban, South Africa
- 18 ⁷IRD Global, Karachi, Pakistan
- 19 ⁸Centers for Disease Control and Prevention, Directorate General Health Services, Sindh, Pakistan
- 20 ⁹IRD Global, Jakarta, Indonesia
- 21 ¹⁰The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-
- 22 Prince, Haiti
- 23 ¹¹TB National TB Center, Kazakhstan
- 24 ¹²Ministry of Health, Addis Ababa, Ethiopia
- 25 ¹³Zanmi Lasante, Cange, Haiti
- 26 ¹⁴Socios en Salud, Lima, Peru
- 27 ¹⁵Médecins Sans Frontières, Tbilisi, Georgia
- 28 ¹⁶Médecins Sans Frontières, Yerevan, Armenia
- 29 ¹⁷Médecins Sans Frontières, Minsk, Belarus
- 30 ¹⁸Médecins Sans Frontières, Yangon, Myanmar
- ¹⁹Partners in Health, Boston, USA 31
- ²⁰Brigham and Women's Hospital, Boston, USA 32
- ²¹Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK 33
- 34 * Contributed Equally
- 35
- 36
- 37 Key words: competing events, inverse-probability weighting, missing follow-up, MDR-TB,
- 38 post-treatment recurrence
- 39
- 40
- 41
- 42
- 43

44 ABSTRACT

- 45 Background: Quantification of recurrence risk following successful treatment is crucial to
- 46 evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB).
- 47 However, such analyses are complicated when some patients die or become lost during post-
- 48 treatment-follow-up.
- 49 Methods: We analyzed data on 1,991 patients who successfully completed a longer MDR/RR-
- 50 TB regimen containing bedaquiline and/or delamanid between 2015 and 2018 in 16 countries.
- 51 Using five approaches for handling post-treatment deaths, we estimated the six-month post-
- 52 treatment TB recurrence risk overall, and by HIV status. We used inverse-probability-weighting
- 53 to account for patients with missing follow-up and investigated the impact of potential bias from
- 54 excluding these patients without applying inverse-probability weights.
- **Results:** The estimated TB recurrence risk was 6.6 per 1000 (95% confidence interval
- 56 (CI):3.2,11.2) when deaths were handled as non-recurrences, and 6.7 per 1000 (95% CI:2.8,12.2)
- 57 when deaths were censored and inverse-probability weights were applied to account for the
- 58 excluded deaths. The estimated risk of composite recurrence outcomes were 24.2 (95%
- 59 CI:14.1,37.0), 10.5 (95% CI:5.6,16.6), and 7.8 (95% CI:3.9,13.2) per 1000 for recurrence or 1)
- any death, 2) death with unknown or TB-related cause, 3) TB-related death, respectively.
- 61 Corresponding relative risks for HIV status varied in direction and magnitude. Exclusion of
- 62 patients with missing follow-up without inverse-probability-weighting had a small but apparent
- 63 impact on estimates.
- 64
- 65 **Conclusion:** The estimated six-month TB recurrence risk was low, and the association with HIV
- status was inconclusive due to few recurrence events. Estimation of post-treatment recurrence
- 67 will be enhanced by explicit assumptions about deaths and appropriate adjustment for missing
- 68 follow-up data.
- 69
- 70
- 71 72 73 74 75 76 77 78 79 80 81 82
- 83
- 84

85 BACKGROUND:

- 86 Quantifying post-treatment tuberculosis (TB) recurrence is critical to evaluating the effectiveness
- 87 of all multidrug- and rifampicin-resistant (MDR/RR) TB regimens during routine care.
- 88 Estimating risk of recurrence is complicated, however, when some patients die or are missing
- 89 data during the post-treatment follow-up (FU) period. Post-treatment deaths that are unrelated to
- 90 TB preclude recurrence and constitute *competing* [1-3] or *intercurrent* [4] events. Conversely, if
- 91 deaths occur due to undetected TB, the risk of recurrence can be underestimated. In analyses of
- 92 recurrence, assumptions are made regarding post-treatment deaths; different assumptions alter
- 93 the estimated quantity and the resulting interpretation [1]. Prior studies have typically 1)
- 94 excluded patients who died [5-8], which will bias the estimated risk of recurrence in the likely
- scenario that people who do and do not die have different underlying risks of TB recurrence; 2)
- 96 effectively assumed that none of the post-treatment deaths were due to recurrent TB [9-10],
- 97 which is not supported by the literature [11-13]; or 3) omitted details on how deaths were
- 98 analyzed [14-18], which prevents a clear interpretation of the resulting estimate.
- 99 Analytic challenges also arise from patients for whom there is no post-treatment follow-up data.
- 100 In these patients, it is unknown whether recurrent TB occurred. Most prior studies that estimate
- 101 TB recurrence have excluded individuals who lack post-treatment follow-up [5-7]. Valid
- 102 estimates under this approach require that individuals who do and do not have post-treatment
- 103 follow-up have a similar underlying risk of recurrent TB. If, on the other hand, there are common
- 104 causes of recurrence and lack of post-treatment follow-up, this assumption does not hold, and
- simply excluding individuals who lack follow-up data may lead to selection bias [19-20].
- 106 In this paper we estimated the overall risk of TB recurrence within six months of successful
- 107 MDR/RR-TB treatment with a longer regimen containing bedaquiline (BDQ) and/or delamanid
- 108 (DLM) and compared this risk among those with and without HIV infection. Compared to
- 109 people without HIV, those with HIV are more susceptible to TB disease [21], at increased risk of
- 110 MDR-TB [22], more prone to serious adverse events [23], and at higher risk of unfavorable
- 111 treatment outcomes, including recurrence [24-25]. In our analyses, we examined multiple
- 112 approaches for handling post-treatment deaths or adjustment for potential bias due to exclusion
- 113 of missing follow-up data and assessed whether results were sensitive to the approach chosen.

114 METHODS

115 Data source and study population.

- 116 We used data from the endTB Observational Study, a prospective cohort of 2,788 individuals
- 117 who initiated a longer individualized MDR/RR-TB regimen containing BDQ and/or DLM
- 118 between 2015 and 2018 in one of seventeen countries (Armenia, Bangladesh, Belarus, Ethiopia,
- 119 Georgia, Haiti, Indonesia, Kazakhstan, Kenya, Kyrgyzstan, Lesotho, Myanmar, North Korea,
- 120 Pakistan, Peru, South Africa, Vietnam) on five continents [26]. For this analysis, we included
- 121 patients' first treatment in endTB, excluded those with confirmed sensitivity to rifampicin and
- restricted to patients with end of treatment success, defined as cure or treatment completion. We
- additionally excluded all individuals from North Korea, as post-treatment follow-up was not
- 124 conducted at this site.
- 125

126 *Outcome measure.*

127 The outcome of interest was a binary indicator of TB recurrence, irrespective of whether it was

- 128 reinfection with a new strain of *Mycobacterium tuberculosis* or relapse with the initial infecting
- 129 strain, within six months of successful treatment. Across participating sites, post-treatment
- 130 outcomes and culture results were recorded by clinicians on a standardized form at scheduled
- 131 visits six months post-treatment. These post-treatment outcomes were classified into the
- 132 following categories: no change, post-treatment death, recurrent TB, lost to follow-up (LTFU),
- 133 and not evaluated. We grouped individuals with the latter two outcomes, or for whom there was
- 134 no post-treatment outcome form, into a single 'missing FU' category.
- 135

136 Statistical methods.

137 <u>Addressing post-treatment deaths.</u> We considered five strategies from the competing/intercurrent

- events literature for handling deaths that occurred within six months post-treatment (Table 1,Figure 1).
- 140

141 First, in what we term the *observed recurrence* strategy, we included patients who died but did

- 142 not count them as recurrences, thereby assuming that patients who died did not experience
- 143 recurrent TB. Second, in the *hypothetical recurrence* strategy [1-4], we excluded patients who
- 144 died and applied stabilized inverse-probability (IP) weights to account for potentially different
- 145 underlying risks of recurrent TB among excluded vs included patients. This strategy posits a
- 146 hypothetical scenario in which all deaths were prevented, so that whether these (in reality
- deceased) patients experienced recurrent TB within six months was observed. Factors associated
- 148 with both post-treatment death and post-treatment recurrence were used in the IP weight
- 149 construction, namely age, CD4 count, cavitary disease, alcohol use, drug use, smoking,
- 150 incarceration, diabetes, stoppage of group A drugs (BDQ, fluoroquinolones, linezolid) due to
- adverse events, and BMI (see Supporting Information for details on weight construction).
- 152
- 153 In strategies 3 through 5, we defined various composite outcomes of recurrence or death. In the
- *observed composite/any* strategy, we included recurrent TB and death from any cause in the outcome, while in the *observed composite/probable* strategy, we included recurrent TB and death
- 155 outcome, while in the observed composite/probable strategy, we included recurrent TB and death
- 156 with unknown or TB-related cause. Finally, in the *observed composite/explicit* strategy, we
- 157 included recurrent TB and only death due to a TB-related cause in the outcome. In the latter two
- 158 composite outcome strategies, we included any deaths not counted in the outcome as non-
- recurrences, thereby assuming that these patients did not experience recurrent TB.
- 160
- 161 Addressing missing post-treatment follow-up data. We utilized stabilized IP weights to overcome
- 162 the potential selection bias induced by excluding patients who lack follow-up data [19-20]. We
- 163 constructed the weight denominators by estimating the probabilities of having an observed six
- 164 month post-treatment outcome conditional on HIV status and joint predictors of missing FU and
- 165 recurrent TB: cavitary disease, BMI, time to culture conversion, use and duration of Group A
- drugs, stoppage of Group A drugs due to an adverse event, likely effectiveness of Group A drugs,
- 167 country of treatment site, and diabetes. See Supporting Information for details.
- 168
- 169 <u>Estimating post-treatment recurrence.</u> We computed estimates of recurrent TB risk, overall and
- by HIV status, by fitting an IP-weighted logistic regression model with the HIV status indicator
- as the only covariate. Weights to account for missing FU were included in all analyses, whereas

- 172 weights to account for common casues of death and recurrent TB were only employed in the
- 173 *hypothetical recurrence* analysis, in which new overall weights were constructed by multiplying
- together the sets of weights. Furthermore, we incorporated an additional set of IP weights in all
- analyses to adjust for potential confounding by the common causes of HIV status and recurrent
- 176 TB, in this case age, country of treatment site, hepatitis C, alcohol use, drug use, smoking, and
- 177 incarceration (see Supporting Information). We constructed 95% credible intervals for all
- 178 estimates with a bootstrapping approach [27] using the boot package in R.
- 179

180 <u>Sensitivity analysis.</u> We conducted a sensitivity analysis to explore how the results from a

- 181 common strategy for handling missing post-treatment follow-up data [5-7] compared to those
- 182 from the IP-weighting approach. In particular, we repeated the analysis described in the previous 183 section, this time without applying IP weights, thereby imposing the assumption that people with
- section, this time without applying IP weights, thereby imposing the assumption that people with and without FU are similar on average with regard to factors that influence recurrence. This
- 185 approach does not account for the potential selection bias induced by excluding patients who
- 186 lack FU data
- 187

188 <u>Simulation Study.</u> Finally, to investigate the impact of potential selection bias in a different data

189 setting, we conducted a simulation study (see Supporting Information). Briefly, we generated an

190 underlying population in which cavitary disease is strongly associated with having missing FU,

191 TB recurrence, and death. We then computed and compared estimates of overall TB recurrence

- risk with and without adjustment for potential selection bias, i.e., with and without weights to
- account for joint predictors of missing FU and TB recurrence. We investigated the impact on
- results of varying different characteristics of the baseline simulation scenario, such as the
- 195 underlying risk of TB recurrence.
- 196

197 **RESULTS**

198 Of the 2,762 patients with confirmed RR/MDR-TB who initiated a longer individualized

regimen containing BDQ and/or DLM, 2,053 (74.3%) patients were cured or completed

- 200 treatment (Figure 2). After removing patients from North Korea, the final dataset we analyzed
- 201 contained 1,991 patients. Among these individuals, 17 (0.9%) died within six-months post-
- treatment, 746 (37.5%) lacked post-treatment follow-up data, and 1228 (61.7%) had an observed
- 203 six-month post treatment-outcome of no change or recurrence.
- 204

205 Table 2 shows the characteristics of the 1,991 patients, overall and by six-month post-treatment 206 outcome. Overall, 11.9% of patients were living with HIV; 21.4% of those who lacked six-month 207 follow-up data and 11.8% of those who died post-treatment had HIV coinfection. The overall 208 patient age distribution was similar to that among patients who were missing FU data or were 209 observed at six-months post-treatment, while patients who died were more likely to be aged 60 210 or older. Compared to patients with follow-up data, patients who lacked follow-up data were 211 more likely to have a body mass index <18.5 and were less likely to have diabetes. The rate of 212 post-treatment deaths and missing follow-up was variable across sites.

212

214 *Six-month risk of TB recurrence*. Ten patients (0.5%) experienced recurrent TB within six-

- 215 months post-treatment with a median time to recurrence of 161 days. Table 3 shows the
- estimated six-month risk of recurrent TB under the five strategies for handling post-treatment
- 217 deaths. The risk of recurrent TB was 6.6 (95% credible interval [CI]: 3.2, 11.2) per 1000

218 individuals under the observed recurrence strategy, and 6.7 (95% CI: 2.8, 12.2) per 1000 under 219 the hypothetical recurrence strategy. The estimated frequencies of a composite outcome under 220 the observed composite/any, observed composite/probable, and observed composite/explicit

221 strategies were 24.2 (95% CI: 14.1, 37.0), 10.5 (95% CI: 5.6, 16.6), and 7.8 (95% CI: 3.9, 13.2) 222 per 1000, respectively.

223

224 *Risk of TB recurrence by HIV status.* The relative risk of recurrent TB in patients with and 225 without HIV under the observed recurrence and hypothetical recurrence strategies were 1.46 226 (95% CI: 0.31, 7.08) and 1.42 (95% CI: 0.30, 7.14), respectively (Table 3). In both cases, relative 227 risks were above one, suggesting a higher risk of recurrence among patients living with HIV; 228 however, confidence intervals were wide. The corresponding risk ratios for the three composite 229 outcomes were 0.62 (95% CI: 0.12, 2.01), 0.85 (95% CI: 0.20, 3.86), and 1.20 (95% CI: 0.25, 230 5.73) for the respectively observed composite/any, observed composite/probable, and observed 231 composite/explicit strategies, respectively.

232

233 Sensitivity analysis. When patients missing post-treatment follow-up were excluded from the 234 analysis without adjustment for potential selection bias, the estimated risk of recurrent TB 235 overall was 7.5 per 1000 (95% CI: 3.9, 11.2) under the observed recurrence strategy, 7.5 per 236 (95% CI: 3.1, 11.8) under the hypothetical recurrence strategy and 20.2 (95% CI: 13.1, 29.3), 237 11.9 (95% CI: 6.6, 18.3), and 9.1 (95% CI: 4.8, 15.4) per 1000 under the three composite 238 strategies (Table 4).

239

240 The impact of potential selection bias was more apparent when looking at estimates of relative 241 risk by HIV status. When results were not adjusted for selection bias, the point estimates differed 242 from the adjusted estimates in terms of magnitude, and in some cases, direction (Table 4).

243

244 *Simulation study.* The results of the simulation study are shown in Table S3-S9 of the

245 Supporting Information. The variation in results across simulation scenarios demonstrates that

246 there are several factors that increase the impact of selection bias, such as a stronger relationship between the joint predictor(s) of missing FU and recurrence and 1) missing FU or 2) recurrence.

- 247
- 248 249

250 DISCUSSION

251 The overall risk of TB recurrence, or risk of TB recurrence or death, was low in this population,

252 substantiating the effectiveness of longer MDR-TB regimens containing BDO and/or DLM. This

253 was true irrespective of method used to handle post-treatment deaths. The association between

254 HIV and TB recurrence was inconclusive due to the small number of recurrences and deaths,

- 255 which resulted in wide confidence intervals across all strategies.
- 256

257 The estimates of TB recurrence and relative risk comparing patients with and without HIV

258 were similar whether derived under the assumption that patients who died post-treatment did not

- 259 experience recurrent TB (observed recurrence) or in a hypothetical scenario where all patient
- 260 deaths could have been prevented (*hypothetical recurrence*). There are other settings in which

261 the difference between these two strategies might be more pronounced; for example, if post-

262 treatment deaths were more common and patients who died had a much higher risk of recurrent

TB compared to patients who did not, then the *hypothetical recurrence* estimate would be markedly higher than the *observed recurrence* estimate.

265

266 As expected, estimates of the six-month incidence of composite outcomes of TB recurrence or 267 death were higher than the estimates for recurrence alone. Furthermore, estimates varied widely 268 depending on which deaths were included in the composite outcome: the incidence of recurrent 269 TB or death from any cause was twice that of recurrent TB or TB-related death, and the risk ratio 270 estimate changed direction depending on whether deaths of unknown cause were included in the 271 outcome or assumed to be non-recurrences. The proportion of post-treatment deaths that are 272 related to TB, and therefore, the importance of incorporating cause of death into composite 273 estimates, will vary by setting and highlights the importance of ascertaining and recording such 274 information.

275

276 The estimates from each strategy answer different questions and in practice, researchers will 277 need to select which one to report [1-4]. Intuitively, the *observed recurrence* strategy may be 278 preferred to the *hypothetical recurrence* strategy, as the latter considers a scenario that is 279 aspirational but not currently relevant to most settings (i.e., one in which all post-treatment 280 deaths could be prevented). On the other hand, the observed recurrence strategy may be 281 inadequate in certain circumstances. For example, if patients with a certain characteristic were 282 much more likely to die post-treatment compared to those without that characteristic, the 283 observed recurrence estimate could indicate that patients with the characteristics are less likely 284 to experience recurrent TB just because earlier death largely prevented this group from 285 developing recurrent TB; see Rojas-Saunero et. al [2] for another example of this. A second 286 scenario in which the *observed recurrence* strategy may not be ideal is when deaths due to 287 undetected TB are common. In this case, one of the composite strategies might be preferable, 288 particularly when complete information on cause of death is available. One potential drawback 289 of the composite strategies is that they change the outcome of interest, which may not always be 290 of scientific interest.

291

292 Patients with low BMI or HIV were more likely, and patients with diabetes were less likely, to 293 have missing FU data in this study. Previous studies have linked each of these subgroups to an 294 increased risk of recurrent TB [8,10,17], which underscores the importance of accounting for 295 patients with missing FU data when estimating recurrent TB. In our sensitivity analysis, the 296 estimates that were computed by excluding patients with missing FU data but without accounting 297 for selection bias through IP-weighting were similar to the IP-weighted estimates of overall 298 recurrence. The differences in the weighted and unweighted relative risk estimates were more 299 pronounced, though wide confidence intervals resulted in the same conclusion. This will not 300 always be the case: larger imbalances in the characteristics of patients with and without FU 301 combined with a stronger association of these characteristics with TB recurrence risk would 302 result in a greater impact of selection bias, and consequently larger differences in the weighted 303 and unweighted estimates. The simulation study of the Supporting Information provides 304 examples of several such settings.

305

This study has several limitations. First, we were not able to distinguish between TB relapse and reinfection. While the rate of reinfection will vary by setting, we sought to limit misclassification

308 by estimating the six-month incidence, a time during which relapse is likely to be the prevailing

309 source of recurrent TB [28]. Second, we considered a less informative binary outcome rather

- than a time to event outcome [6], as follow-up was only consistently reported using a six-month
- 311 post-treatment form at most sites rather than through continuous follow-up. Third, our results on
- HIV as a determinant of recurrence may be affected by collider bias [29-30]. This could occur if there is a factor such as age that is associated with both HIV status and inclusion in the cohort. If
- there is a factor such as age that is associated with both HIV status and inclusion in the cohort. If a third factor, such as TB disease severity, is associated with cohort inclusion and recurrent TB
- 314 a third factor, such as TB disease seventy, is associated with conort inclusion and recurrent TB 315 risk, the relationship observed between HIV status and recurrent TB may be distorted. This is a
- challenge with all observational TB studies, as TB is more likely to go undetected among people
- 17 living with HIV [31]. Therefore, this group is less likely to be included in a treatment cohort.
- 318 This bias could be reduced through IP-weighting if data were available on factors related to 1) to
- 319 HIV status and cohort inclusion and 2) cohort inclusion and experiencing post-treament TB
- 320 recurrence. Unfortunately, this information is often unattainable in practice, as it requires being
- able to identify all people living with HIV who are eligible for MDR-TB treatment.
- 322 As multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) treatment guidelines evolve
- in response to emerging evidence [32-34] on the relative safety and effectiveness of all-oral
- 324 shortened regimens compared to conventional longer treatments, an important and currently
- unanswered question is whether the relative safety and effectiveness of shortened vs longer
- regimens differ across important patient subgroups, such as people living with HIV [35].
- Rigorous analyses of post-TB treatment recurrence are needed to accurately understand whether
- 328 certain groups may require closer monitoring, given possible increased risk of relapse [36-38]
 329 relative to longer regimens. While methods for handling competing events and potential
- significative to longer regimens. while methods for handling competing events and potential selection bias due to losses to follow-up are well-established [4, 19-20], their use in the context
- of estimating TB recurrence is sparse. Careful handling of post-treatment deaths and missing
- 32 post-treatment follow-up data together with accompanying sensitivity analyses will generate
- evidence that is more robust and interpretable, with the overall goal of improving treatment and
- 334 care.
- Funding. The endTB observational study was funded by UNITAID. SMS was supported by the
 National Institutes of Allergy and Infectious Diseases under Award Number T32 AI007433.
 MFF, CDM, KS, and MR were supported by the National Institutes of Allergy and Infectious
- 338 Diseases under Award Number R01AI46095. The funders had no role in the conceptualization,
- analysis, or presentation of findings of this study.
- 340 Acknowledgements. The authors thank the patients who participated in the endTB
- 341 Observational Study and the clinicians and program staff of participating national tuberculosis
- 342 programs. They also thank the endTB staff at Partners in Health, Doctors Without Borders,
- 343 Epicentre, and Interactive Research and Development.
- 344
- 345 Author contributions. SMS, CDM, and MF led the conceptualization, data curation,
- 346 methodology, analysis, and writing of the paper. CDM, MF, MR, KS, UK, PK MB, CH, and HH
- 347 led the design of the endTB study. UK, CH, MB, DH, SL, MK, SP, SA, AKI, A Krisnanda,
- 348 SCV, SB, A Kumsa, WD, KT, MM, HA, TV, TTT, KS, MR, HH, and PK contributed to data
- 349 collection and curation. All authors contributed to editing and review of the paper.
- 350

- 351 Data availability statement. Some of the data included in this analysis are managed in countries
- 352 governed by the European Union General Data Protection Regulation (GDPR). The data contain
- 353 sensitive and potentially identifying information and cannot be sufficiently anonymized to meet
- 354 GDPR standards and retain their utility. Pseudo-anonymized data will be made available upon
- 355 request to an MSF Medical Director at endTB.ClinicalTrial@paris.msf.org, and execution of a
- data sharing agreement or alternate means that allows assurance that principles of GDPR
- 357 regulations will be met.
- 358
- 359 Conflict of interest. CDM has served as a board member of Otsuka Scientific Advisory Board.
 360 All other authors report no potential conflicts.
- 361

373 374

375

379

380

381

362 **References**

- Young JG, Stensrud MJ, Tchetgen Tchetgen EJ, et al. "A causal framework for classical statistical estimands in failure □ time settings with competing events." *Statistics in Medicine*. 2020; 39(8):1199-1236. doi:10.1002/sim.8471
- Rojas-Saunero PL, Young JG, Didelez V, et al. "Choosing questions before methods in dementia research with competing events and causal goals." *American Journal of Epidemiology*.2023. doi:10.1093/aje/kwad090
- 369
 3. Chiu YH, Stensrud MJ, Dahabreh IJ, et al. "The effect of prenatal treatments on offspring events in the presence of competing events: an application to a randomized trial of fertility therapies." *Epidemiology*. 2020; 31(5):636-643. doi: 10.1097/EDE.00000000001222
 - Pham TM, Tweed CD, Carpenter DR, et al. "Rethinking intercurrent events in defining estimands for tuberculosis trials." *Clinical Trials*. 2022; 19(5): 522-533. doi: 10.1177/17407745221103853
- 5. Franke MF, Appleton SC, Mitnick CD, et al. "Aggressive regimens for multidrugresistant tuberculosis reduce recurrence." *Clinical Infectious Diseases*. 2013; 56(6): 770776. doi:10.1093/cid/cis1008
 - Becerra MC, Appleton SC, Franke MF, et al. "Recurrence after treatment for pulmonary multidrug-resistant tuberculosis." *Clinical Infectious Diseases*. 2010; 51(6): 709–11. doi: 10.1086/655892
- 382
 382
 7. Schwæbel V, Trébucq A, Kashongwe Z, et al. "Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries." *EClinicalMedicine*. 2020; 20: 100268. doi: 10.1016/j.eclinm.2020.100268.
- Chiang CY, Enarson DA, Yu MC, et al. "Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study." *European Respiratory Journal*. 2006; 28:980–985. doi: 10.1183/09031936.06.00125705
- 389
 9. Kim DH, Kim HJ, Park SK, et al. "Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis". American Journal of Respiratory and Critical Care Medicine." 2008; 178(10):1075–1082. doi: 10.1164/rccm.200801-132OC
- 393 10. Shin SS, Furin JJ, Alcántara F, et al. "Long-term follow-up for multidrug-resistant 394 tuberculosis." *Emerging Infectious Diseases*. 2006; 12(4):687–688. doi: 395 10.3201/eid1204.041256


396	11.	Mathema B, Kurepina NE, Bifani PJ, et al. "Molecular epidemiology of tuberculosis:
397		Current insights." Clinical Microbiology Reviews. 2006;19(4):658-685. doi:
398		10.1128/CMR.00061-05
399	12	Panjabi R, Comstock GW, Golub JE. "Recurrent tuberculosis and its risk factors:
400		Adequately treated patients are still at high risk." The International Journal of
401		Tuberculosis and Lung Disease. 2007;11(8):828-837.
402	13	. Takarinda KC, Sandy C, Masuka N, et al. "Factors associated with mortality among
403		patients on TB treatment in the southern region of Zimbabwe." Tuberculosis Research
404		and Treatment. 2017. doi: 10.1155/2017/6232071
405	14	. Khan FA, Gelmanova IY, Franke MF, et. al. "Aggressive regimens reduce risk of
406		recurrence after successful treatment of MDR-TB." Clinical Infectious Diseases. 2016;
407		63(2): 214-220. doi: 10.1093/cid/ciw276.
408	15	Lee J, Lim HJ, Cho YJ, et al. "Recurrence after successful treatment among patients with
409		multidrug-resistant tuberculosis." International Journal of Tuberculosis and Lung
410		Disease. 2011; 15(10): 1331–1333. doi: 10.5588/ijtld.11.0098
411	16	. Cavanaugh JS, Kazennyy BY, Nguyen ML, et al. "Outcomes and follow-up of patients
412	10	treated for multidrug-resistant tuberculosis in Orel, Russia, 2002–2005." <i>International</i>
413		Journal of Tuberculosis and Lung Disease. 2012; 16(8): 1069–1074. doi:
414		10.5588/ijtld.11.0696
415	17	Leung EC, Yew WW, Leung CC, et al. "Shorter treatment duration for selected patients
416		with multidrug-resistant tuberculosis." <i>European Respiratory Journal</i> . 2011; 38: 227–
417		230. doi: 10.1183/09031936.00186310
418	18	. Aung KJ, Van Deun A, Declercq E, et al. "Successful '9-month Bangladesh regimen' for
419		multidrug-resistant tuberculosis among over 500 consecutive patients." <i>International</i>
420		Journal of Tuberculosis and Lung Disease. 2014; 18(10): 1180–1187. doi:
421		10.5588/ijtld.14.0100
422	19	. Hernán MA, Hernández-Díaz S, Robins JM. "A structural approach to selection bias.
423		Epidemiology." 2004; 15(5): 615-625. doi:
424	20	Hernán MA, Robins JM. "Chapter 8: Selection Bias." Causal Inference: What If. 2020.
425		Boca Raton: Chapman & Hall/CRC.
426	21	. World Health Organization. "Global Tuberculosis Report." 2022. Available at:
427		https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-
428		tuberculosis- report-2022
429	22	. Sultana ZZ, Hoque FU, Beyene J, et al. "HIV infection and multidrug resistant
430		tuberculosis: a systematic review and meta-analysis." BMC Infectious Diseases. 2021;
431		21(1): 1-13. doi: 10.1186/s12879-020- 05749-2
432	23	Hong H, Budhathoki C, Farley JE. "Increased risk of aminoglycoside-induced hearing
433		loss in MDR-TB patients with HIV coinfection." International Journal of Tuberculosis
434		and Lung Disease. 2018; 22(6): 667-674. doi: 10.5588/ijtld.17.0830
435	24	Loveday M, Reuter A, Furin J, et al. "The STREAM trial: missed opportunities and
436		lessons for future clinical trials." Lancet Infectious Diseases. 2019; 19(4): 351-353. doi:
437		10.1016/S1473-3099(19)30106-9
438	25	Imperial MZ, Nahid P, Phillips PPJ, et al. "A patient-level pooled analysis of treatment
439		shortening regimens for drug-susceptible pulmonary tuberculosis." Nature Medicine.
440		2018; 24: 1708–1715. doi: 10.1038/s41591-018-0224-2

481	
480	1587. doi:10.1056/NEJMoa1407426.
479	for drug-sensitive tuberculosis." New England Journal of Medicine. 2014; 371(17): 1577-
478	38. Gillespie SH, Crook AM, McHugh TD, et al. "Four-month moxifloxacin-based regimens
477	doi: 10.1056/NEJMoa1314210.
476	pulmonary tuberculosis." New England Journal of Medicine. 2014; 371(17): 1599-1608.
475	37. Jindani A, Harrison TS, Nunn AJ, et al. "High-dose rifapentine with moxifloxacin for
474	doi:10.1056/NEJMoa1315817.
473	treating tuberculosis." New England Journal of Medicine. 2014; 371(17): 1588-1598.
472	36. Merle CS, Fielding K, Sow OB, et al. "A Four-month gatifloxacin-containing regimen for
471	https://www.who.int/publications/i/item/9789240063129
470	treatment: drug-resistant tuberculosis treatment." 2022. Available at:
469	35. World Health Organization. "WHO consolidated guidelines on tuberculosis: module 4:
468	2022; 400(10366): 1858-1868. doi: 10.1016/S0140-6736(22)02078-5
467	open-label, multicentre, randomised, non-inferiority trial." <i>The Lancet</i> .
466	regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an
465	34. Goodall RL, Meredith SK, Nunn AJ, et al. "Evaluation of two short standardised
464	doi: 10.1056/NEJMoa2117166
463	resistant tuberculosis." <i>New England Journal of Medicine</i> . 2022; 387(25): 2331-2343.
462	33. Nyang'wa BT, Berry C, Kazounis E, et al. "A 24-week, all-oral regimen for rifampin-
461	of the Nix-TB trial." <i>Clinical Infectious Diseases</i> . 2023: doi: 10.1093/cid/ciad051
460	32. Solans BP, Imperial MZ, and Olugbosi M, et al. "Analysis of dynamic efficacy endpoints of the Nin TP trial." <i>Clinical Infectious Diseases</i> 2022; doi: 10.1002/cid/ciad051
459 460	10.4102/phcfm.v9i1.1406 32 Solons RP. Imperial MZ and Olughosi M. et al. "Analysis of dynamic officeasy and points
	African Journal Primary Health Care and Family Medicine. 2017; 9(1): 1-6. doi: 10.4102/phofm.v0i1.1406
457 458	
430 457	patients with HIV infection who present with severe anaemia at a district hospital."
4 <i>5</i> 5 456	31. Mntonintshi M, Mabunda S, Namugenyi KAF, et al. "Undiagnosed tuberculosis in
454 455	soc-071913-043455
453 454	collider variable." Annual Review of Sociology. 2014; 40: 31–53. doi: 10.1146/annurev-
4 <i>52</i> 453	30. Elwert F and Winship C. "Endogenous selection bias: the problem of conditioning on a
452	10.1093/ije/dyp334
450 451	collider." International Journal of Epidemiology. 2010; 39: 417–420. doi:
449	29. Cole SR, Platt RW, Schisterman EF, et al. "Illustrating bias due to conditioning on a
448 449	Infectious Diseases. 2014; 58(12): 1676-1683. doi: 10.1093/cid/ciu186
448	reinfection tuberculosis after successful treatment: a retrospective cohort study." <i>Clinical</i>
447	28. Marx FM, Dunbar R, Enarson DA, et al. "The temporal dynamics of relapse and
446	Cambridge University Press.
445	27. Davison AC and Hinkley DV. <i>Bootstrap Methods and Their Application</i> . 1997.
444	019-4378-4
443	containing regimens." BMC Infectious Diseases. 2019; 19(1): 1-9. doi: 10.1186/s12879-
442	Observational Study Protocol: Treatment of MDR-TB with bedaquiline or delamanid
441	26. Khan U, Huerga H, Khan AJ, et al. "The endTB (Expand New Drugs for TB)


482

483

- 484 **Figure 1:** Graphical representation of the association between HIV and recurrent TB at six
- 485 months post-treatment. The *observed recurrence* strategy estimates paths *a* and *b*-*c*; the
- 486 *hypothetical recurrence* strategy estimates path *a* only, adjusting for common causes of death
- 487 within six months post-treatment (prior to recurrence) and recurrent TB (L_1) to eliminate bias
- 488 through the *b*-*d*-*e* path; adjustment for the joint predictors of missing FU (L_2) accounts for
- 489 potential selection bias through the f-g-h path; adjustment for common causes of HIV infection
- 490 and recurrent TB (L_3) addresses potential confounding bias by blocking the *i*-*j* path.
- 491



512 **Figure 2**: Inclusion/exclusion criteria for the post-treatment analysis



535 Table 1: Strategies for handling deaths post-treatment

Approach	Operationalization	Assumptions
Observed recurrence ¹	Include individuals who	Patients who died did not
	died in the analysis and	experience recurrent TB
	treat as non-recurrences ⁴	
Hypothetical recurrence ²	Censor (exclude)	All common causes of death
	individuals who died,	and recurrence have been
	account for common	accounted for
	causes of death and	
	recurrence with IP weights	
Observed composite/any³	Define a composite	
· ·	outcome of recurrence or	
	death from any cause	
Observed	Define a composite	Patients with deaths unrelated
composite/probable ³	outcome of recurrence or	to TB did not experience
	death with either 1)	recurrent TB
	unknown cause, 2) cause	
	related to TB; treat deaths	
	with cause unrelated to TB	
	as non-recurrences ⁴	
Observed	Define a composite	Patients with deaths of
composite/explicit ³	outcome of recurrence or	unknown cause or cause
1 1	death with cause related to	unrelated to TB did not
	TB, treat deaths with 1)	experience recurrent TB
	unknown cause and 2)	1
	cause unrelated to TB as	
	non-recurrences ⁴	
hen estimating the association betw		ce the observed recurrence strategy

536 537 when estimating the association between HIV and post-treatment recurrence, the observed recurrence strategy

corresponds to estimating the total effect of HIV in the causal inference with competing events literature [1-3]

538 2 in the causal inference literature, the quantity estimated through the hypothetical recurrence strategy is known as 539 the controlled direct effect [1-3]; in the intercurrent events literature, the corresponding strategy is called the

540 *hypothetical* strategy [4]

541 ³composite strategies correspond to estimating the *total effect on a composite event* in the causal inference literature

542 [1-3], and as the *composite* strategy in the corresponding intercurrent events literature [4]

⁴recurrent TB outcome indicator set to 0 for all patients handled as non-recurrences 543

- 544
- 545
- 546
- 547
- 548

549

		~ .				
550	Table 2.	Summary of n	atient characte	pristics by si	iv-month r	oost-treatment outcome.
550	I abic 2.	Summary of p	anom charact	mones by si	in monui p	Jost treatment outcome.

Characteristic	Overall	Observed	LTFU	Died
	(%)	(%)	(%)	(%)
	n=1991	n=1228	n=746	n=17
HIV				
Yes	237 (11.9)	75 (6.1)	160 (21.4)	2 (11.8)
No	1754 (88.1)	1153 (93.9)	586 (80.2)	15 (88.2)
Age				
0-19	161 (8.1)	87 (7.1)	73 (9.8)	1 (5.9)
20-44	1296 (65.1)	814 (66.3)	474 (63.5)	8 (47.1)
45-59	435 (21.8)	274 (22.3)	157 (21.0)	4 (23.5)
60+	99 (5.0)	53 (4.3)	42 (5.6)	4 (23.5)
BMI <18.5kg				
Yes	423 (21.2)	215 (17.5)	197 (26.4)	11 (64.7)
No	1568 (78.8)	1013 (82.5)	549 (73.6)	6 (35.3)
Diabetes mellitus				
Yes	295 (14.8)	189 (15.4)	103 (13.8)	3 (17.6)
No	1669 (83.8)	1031 (84.0)	624 (83.6)	14 (82.4)
Missing	27 (1.4)	8 (0.7)	19 (2.5)	0 (0.0)
Hepatitis C				
Yes	185 (9.3)	130 (10.6)	53 (7.1)	2 (11.8)
No	1806 (90.7)	1098 (89.4)	693 (92.9)	15 (88.2)
Cavitary disease				~ /
Yes	682 (34.3)	436 (35.5)	239 (32.06)	7 (41.2)
No	1197 (60.1)	756 (61.6)	432 (57.9)	9 (52.9)
Missing	112 (5.6)	36 (2.9)	75 (10.1)	1 (5.9)
BDQ use				· · · · ·
\geq 6 months	1466 (73.6)	930 (75.7)	523 (70.1)	13 (76.5)
< 6 months	525 (26.4)	298 (24.3)	223 (29.9)	4 (23.5)
FQ ever used				
Yes	1341(67.4)	819 (66.7)	510 (68.4)	12 (70.6)
No	650 (32.6)	409 (33.3)	236 (31.6)	5 (29.4)
LZD ever used				
Yes	1787 (89.8)	1149 (93.6)	622 (83.4)	16 (94.1)
No	204 (10.2)	79 (6.4)	124 (16.6)	1 (5.9)
Study site				
Central Asia	583 (29.3)	373 (30.4)	206 (27.6)	4 (23.5)
East or Southeast Asia	94 (4.7)	27 (2.2)	64 (8.6)	3 (17.6)
South Asia	455 (22.9)	280 (22.8)	170 (22.8)	5 (29.4)
Western Asia	276 (13.9)	217 (17.7)	56 (7.5)	3 (17.6)
Europe	82 (4.1)	65 (5.3)	17 (2.3)	0 (0.0)
Sub-Saharan Africa	264 (13.3)	54 (4.4)	208 (25.9)	2 (11.8)
South	237 (11.9)	212 (17.3)	25 (3.4)	0 (0.0)
America/Caribbean	, , ,	. ,		

- 551 **Table 3:** Estimated risk of recurrence overall and by HIV status under five strategies for
- 552 handling post-treatment deaths.

Strategy		Relative risk ¹		
	Overall	With HIV	Without HIV	
Observed	6.6	9.2	6.3	1.46
recurrence	(3.2, 11.2)	(2.0, 31.7)	(2.9, 10.8)	(0.31, 7.08)
Hypothetical	6.7	9.0	6.4	1.42
recurrence	(2.8, 12.2)	(2.1, 33.5)	(2.2, 11.5)	(0.30, 7.14)
Observed	24.2	15.6	25.3	0.62
composite/any	(14.1, 37.0)	(2.8, 42.4)	(14.6, 40.0)	(0.12, 2.01)
Observed	10.5	9.2	10.7	0.85
composite/probable	(5.6, 16.6)	(2.1, 32.6)	(5.1, 16.7)	(0.20, 3.86)
Observed	7.8	9.2	7.6	1.20
composite/explicit	(3.9, 13.2)	(2.1, 32.6)	(3.4, 13.1)	(0.25, 5.73)

¹95% credible intervals are constructed as the 2.5th and 97.5th percentiles of the 1000 bootstrap sample estimates 554

555

Table 4: Sensitivity analysis results; estimated risk of recurrence overall and by HIV status

557 under five strategies for handling post-treatment deaths, without IP-weighting to account for

558 excluded patients with missing FU data.

Strategy	tegy Risk per 1000 ¹				
	Overall	With HIV	Without HIV		
Observed	7.5	14.0	6.6	2.13	
recurrence	(3.9, 11.2)	(4.3, 44.3)	(3.2, 11.0)	(0.64, 9.12)	
Hypothetical	7.5	13.3	6.7	1.99	
recurrence	(3.1, 11.8)	(4.2, 42.0)	(2.4, 12.3)	(0.56, 10.14)	
Observed	20.2	25.9	19.4	1.33	
composite/any	(13.1, 29.3)	(5.9, 65.0)	(11.8, 28.3)	(0.31, 3.47)	
Observed	11.9	14.0	11.7	1.20	
composite/probable	(6.6, 18.3)	(4.4, 42.2)	(5.8, 17.8)	(0.38, 4.38)	
Observed	9.1	14.0	8.4	1.66	
composite/explicit	(4.8, 15.4)	(4.4, 42.2)	(3.4, 14.3)	(0.47, 6.63)	

559

9 ¹95% credible intervals are constructed as the 2.5th and 97.5th percentiles of the 1000 bootstrap sample estimates